Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sindilizumab plus SOX versus SOX alone for perioperative treatment of locally advanced gastric cancer
ChiCTR2400091057Phase 2Recruiting
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Oct 2024
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sindilizumab, oxaliplatin and tegafur + gimeracil + oteracil in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Pathological complete response rate. Started Oct 2024; status: recruiting.
02
Drugs
sindilizumaboxaliplatintegafur + gimeracil + oteracil
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2400091057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091057.